Accéder au contenu
Merck

Cholesterol as a modulator of cannabinoid receptor CB2 signaling.

Scientific reports (2021-02-14)
Alexei Yeliseev, Malliga R Iyer, Thomas T Joseph, Nathan J Coffey, Resat Cinar, Lioudmila Zoubak, George Kunos, Klaus Gawrisch
RÉSUMÉ

Signaling through integral membrane G protein-coupled receptors (GPCRs) is influenced by lipid composition of cell membranes. By using novel high affinity ligands of human cannabinoid receptor CB2, we demonstrate that cholesterol increases basal activation levels of the receptor and alters the pharmacological categorization of these ligands. Our results revealed that (2-(6-chloro-2-((2,2,3,3-tetramethylcyclopropane-1-carbonyl)imino)benzo[d]thiazol-3(2H)-yl)ethyl acetate ligand (MRI-2646) acts as a partial agonist of CB2 in membranes devoid of cholesterol and as a neutral antagonist or a partial inverse agonist in cholesterol-containing membranes. The differential effects of a specific ligand on activation of CB2 in different types of membranes may have implications for screening of drug candidates in a search of modulators of GPCR activity. MD simulation suggests that cholesterol exerts an allosteric effect on the intracellular regions of the receptor that interact with the G-protein complex thereby altering the recruitment of G protein.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
ChemiSCREEN Membrane Preparation Recombinant Human CB2 Cannabinoid Receptor, Human CB2 GPCR membrane preparation for Radioligand binding Assays & GTPγS binding.